Company Proposes Reverse Stock Split (1-for-30 to 1-for-50) to Avoid Nasdaq Delisting

summarizeSummary

Cue Biopharma is seeking stockholder approval for a reverse stock split (1-for-30 to 1-for-50) to prevent Nasdaq delisting, a critical move amidst significant executive changes and compliance issues.

check_boxKey Events

• Proposed Reverse Stock Split

  Stockholders will vote on an amendment to effect a reverse stock split at a ratio between 1-for-30 and 1-for-50. This is primarily to increase the per-share price to meet Nasdaq's minimum bid price requirement and avoid delisting, with a compliance deadline of May 11, 2026.

• Significant Executive Turnover

  The former CEO, Daniel R. Passeri, retired in September 2025, receiving $838,750 in severance. The former Chief Medical Officer, Matteo Levisetti, was terminated in November 2025, receiving $556,838 in severance. Usman Azam was appointed President and CEO in September 2025, and Lucinda Warren became Chief Financial and Business Officer in February 2026.

• Compliance Reporting Lapses

  Several executive officers, including the CEO (Usman Azam), CFO (Lucinda Warren), and SVP (Colin Sandercock), filed late Form 4 reports in late 2025, indicating a lapse in compliance with Section 16(a) reporting requirements.

• Ongoing Capital Raises with Major Shareholder Participation

  Affiliates of Bleichroeder LP, a more than 5% owner, participated in underwritten public offerings in September 2024 ($2.497M), April 2025 ($2.498M), and December 2025 ($1.000M), highlighting the company's continuous need for capital and reliance on existing large investors.

auto_awesomeAnalysis

Cue Biopharma's proposal for a reverse stock split, ranging from 1-for-30 to 1-for-50, is a critical measure to maintain its Nasdaq listing and avoid delisting due to its stock price falling below the $1.00 minimum bid requirement. For a micro-cap company like Cue Biopharma, delisting would severely impact liquidity and investor interest, making this a necessary, albeit often negatively perceived, step for survival. This significant corporate action coincides with substantial executive turnover, including the departure of the former CEO and CMO with considerable severance packages, and the appointment of new C-suite leadership. Additionally, multiple late Form 4 filings by key executives indicate compliance weaknesses. Investors should closely monitor the outcome of the reverse split vote and its subsequent effect on the company's listing status and market perception, as well as the stability and performance of the new leadership team.